A large-scale randomised controlled trial in Taiwan reveals that the use of an artificial intelligence-enabled electrocardiogram alert system can significantly reduce mortality in hospitalized patients, Nature Medicine

This article on the use of an artificial intelligence alert system is not new but it was mentioned during the recent European Society of Cardiology CRT – Cardiovascular Round Table – on the them of AI in cardiovascular care, which took place on March 26-27, 2025 (link) The primary clinical hypothesis of this randomised controlled […]

A large-scale randomised controlled trial in Taiwan reveals that the use of an artificial intelligence-enabled electrocardiogram alert system can significantly reduce mortality in hospitalized patients, Nature Medicine Read Post »

Patient participation at the 2nd European Society of Cardiology CRT, Cardiovascular Round Table, on “How can cardiologists take the lead in moving AI forward”, Guermantes, France, March 26-27, 2025

The European Society of Cardiology‘s 2025 CRT – Cardiovascular Round Table – took place on 26-27 March in Guermantes, France. This gathering united approximately 80 participants representing the scientific community, pharma and tech industries, and patient advocates, to explore the transformative theme “Working together to move forward AI in cardiology.” The meeting carefully balanced informative

Patient participation at the 2nd European Society of Cardiology CRT, Cardiovascular Round Table, on “How can cardiologists take the lead in moving AI forward”, Guermantes, France, March 26-27, 2025 Read Post »

March is Nutrition Month in the US, here are some tips from the US Pulmonary Hypertension Association, PHA

March is National Nutrition Month in the US, and the Pulmonary Hypertension Association has shared a LinkedIn post highlighting nutrition awareness for pulmonary hypertension patients. The organization encourages patients to be especially mindful of their dietary choices, as certain foods and vitamins can adversely interact with pulmonary hypertension medications, worsen edema (fluid retention), or exacerbate

March is Nutrition Month in the US, here are some tips from the US Pulmonary Hypertension Association, PHA Read Post »

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025

This article, published in the International Journal of Cardiology Congenital Heart Disease in March 2025, discusses pulmonary hypertension in pregnancy, historically associated with poor outcomes, and provides recent evidence suggesting that the prognosis varies based on underlying cause and severity. The authors emphasize the need for individualized care through a multidisciplinary team approach at tertiary

Pregnancy and pulmonary arterial hypertension: Management challenges, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

Latest edition of “Pathlight”, the US Pulmonary Hypertension Association’s quarterly magazine, now out!

The latest issue of the quarterly Pathlight magazine of the US Pulmonary Hypertension Association, the PHA, celebrates pulmonary hypertension heroes. As National Volunteer Month approaches, the association acknowledges the people who make this organization a success. This issue also includes articles about imaging innovations, managing medication side effects and swimming with subcutaneous therapy.  To receive

Latest edition of “Pathlight”, the US Pulmonary Hypertension Association’s quarterly magazine, now out! Read Post »

How family dynamics are affected in the case of a genetic pulmonary arterial hypertension diagnosis: interview and focus group highlights, European Respiratory Journal Open research, March 24, 2025

A study titled “Navigating family dynamics and ethical considerations in genetic diagnosis of pulmonary arterial hypertension: insights from in-depth semi-structured interviews”, published on the ERJ Open research on March 24, 2025, examines the impact of genetic diagnosis on families affected by pulmonary arterial hypertension (PAH). Researchers interviewed 63 stakeholders across 53 interviews and focus groups

How family dynamics are affected in the case of a genetic pulmonary arterial hypertension diagnosis: interview and focus group highlights, European Respiratory Journal Open research, March 24, 2025 Read Post »

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025

In a multicenter study from the FOCUS-PAH registry (2001-2022), researchers examined sex differences among 410 pulmonary arterial hypertension patients, and found that women represented 2 out of 3 patients (66.6 %) vs 33.4%). The findings, published in the International Journal of Cardiology on March 20, 2025 in an article titled “Sex differences in pulmonary arterial

Should sex differences be taken into account when conducting a risk assessment for pulmonary arterial hypertension patients? International Journal of Cardiology, March 20, 2025 Read Post »

Advancing pulmonary hypertension care at the ERN-Lung Annual Board meeting, Paris, March 24-25, 2025

The annual Board meeting of the ERN-LUNG – European Reference Network for rare respiratory diseases, took place in Paris on March 24-25, 2025, with over 100 participants, not only from the EU but also UK, US and Canada. Two European patient representatives, Pisana Ferrari and Hall Skaara, (2nd and 3rd from left in the cover

Advancing pulmonary hypertension care at the ERN-Lung Annual Board meeting, Paris, March 24-25, 2025 Read Post »

Diagnostic Delays and Quality of Life in Japanese Patients with Pulmonary Hypertension: A Nationwide Survey, Pulmonary Therapy, March 18, 2025

A study published on March 18 2025 in Pulmonary Therapy provides a comprehensive view of pulmonary hypertension in Japan through a nationwide survey of 160 patients (119 with pulmonary arterial hypertension (PAH) and 41 with chronic thromboembolic pulmonary hypertension (CTEPH) and 211 physicians. We are particularly pleased to publish this article as one of the

Diagnostic Delays and Quality of Life in Japanese Patients with Pulmonary Hypertension: A Nationwide Survey, Pulmonary Therapy, March 18, 2025 Read Post »

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025

This review, published on Expert Opinion on Pharmacotherapy on March 19, 2025, chronicles the evolution of pulmonary arterial hypertension (PAH) treatment from historical milestones to current challenges. Beginning with Ernst von Romberg’s first clinical description in 1891 and the advent of cardiac catheterization, pulmonary arterial hypertension diagnosis and treatment have advanced significantly in past decades.

Historical milestones and future horizons: exploring the diagnosis and treatment evolution of the pulmonary arterial hypertension in adults, Expert opinion on pharmacotherapy, March 19, 2025 Read Post »

Living with Pulmonary Arterial Hypertension: Early Diagnosis, Patient Advocacy, and the Role of Technology, Maleen Fischer, Cambridge Network News, electronRx blog

Maleen Fischer, whose “blue lips” in infancy were dismissed by doctors for nearly four years before receiving a diagnosis of pulmonary arterial hypertension at age four. In a recent article for Cambridge Network News and in a blog for electronRx she shares how despite years on continuous IV medication and isolation during childhood and adolescence,

Living with Pulmonary Arterial Hypertension: Early Diagnosis, Patient Advocacy, and the Role of Technology, Maleen Fischer, Cambridge Network News, electronRx blog Read Post »

Jimmy Ford MD discusses the work of the “Patient Perspectives” Taks force at the 7th World Symposium on Pulmonary Hypertension in a podcast for phaware Global Association

Jimmy Ford, MD discusses the 7th World Symposium on Pulmonary Hypertension and his work on the “Patient Perspectives” Task Force, check out the PHAWARE GLOBAL ASSOCIATION podcast, episode 512 at this link The “Patient Perspectives” Task Force was composed of four patient representatives, three of which are patients (Pisana Ferrari, Italy; Hall Skaara, Norway, and

Jimmy Ford MD discusses the work of the “Patient Perspectives” Taks force at the 7th World Symposium on Pulmonary Hypertension in a podcast for phaware Global Association Read Post »

Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025

Corsair Pharma, Inc. is a private biopharmaceutical company. The company has just announced the successful completion of a preclinical program for Its treprostinil Prodrug Transdermal System and its plans to start a Phase 1 trial in Q2 of 2025. The Corsair transdermal patch is intended to provide steady and continuous blood levels of the prostacyclin

Corsair Pharma Inc. announces plans to launch a Phase 1 trial of a treprostinil skin patch for pulmonary arterial hypertension, March 17, 2025 Read Post »

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025

A recent study published in ESC Heart Failure (March 4, 2025) compared initial monotherapy versus combination therapy in pulmonary arterial hypertension (PAH) patients with cardiovascular comorbidities. Results showed that the combination therapy group experienced greater improvements in functional class, BNP/NT-proBNP levels, and overall risk status compared to monotherapy patients. However, no significant differences were observed

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis, ESC Heart Failure, March 4, 2025 Read Post »

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025)

A recent analysis published in the International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) examines the evolving landscape of pulmonary arterial hypertension (PAH). While traditionally viewed as primarily affecting young adult women without other health conditions, newer registry data from developed countries reveals a shift toward older patients with multiple co-morbidities like

“Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox”, International Journal of Cardiology Congenital Heart Disease (Volume 9, March 2025) Read Post »

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025

The authors of the study “Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document” published in the Hellenic Journal of Cardiology on February 19, 2025, presents a country-specific approach to care developed by a multidisciplinary team of cardiologists, pulmonologists, and intensivists. The authors discuss the advances in the field of

Revisiting treatment of pulmonary arterial hypertension in the current era: A Greek scientific document, Hellenic Journal of Cardiology, February 19, 2025 Read Post »

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025

The authors of a study titled “Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling”, published in the British Journal of Pharmacology on Ferbruary 20, 2025, present an innovative technique to allow proxy evaluation of human pulmonary artery contractility. Vasoreactivity of the pulmonary arteries regulates blood flow through the lungs,they say, and

Miniature three dimensional arterial structures may allow proxy evaluation of human pulmonary artery contractility, British Journal of Pharmacology, February 20, 2025 Read Post »

The Aeson Total Artificial Heart helps three heart failure patients with pulmonary hypertension become heart transplant-eligible, The Journal of Heart and Lung Transplantation, February 5, 2025

Three heart failure patients with pulmonary hypertension (WHO Group II) became eligible for heart transplants after receiving the Aeson Total Artificial Heart, which effectively took place after 243, 155 and 109 days respectively. This innovative device, implanted with the help of the advanced Carmat system, replaces the heart’s ventricles and maintains continuous blood circulation, stabilizing

The Aeson Total Artificial Heart helps three heart failure patients with pulmonary hypertension become heart transplant-eligible, The Journal of Heart and Lung Transplantation, February 5, 2025 Read Post »

Cereno Scientific launches sub-study on drug candidate CS1 for Pulmonary Arterial Hypertension, February 19, 2025

Cereno Scientific has received approval to initiate a sub-study within its Expanded Access Program (EAP) for CS1, a drug candidate aimed at treating pulmonary arterial hypertension. The study will use Functional Respiratory Imaging (FRI) technology, developed by Fluidda, to monitor changes in small pulmonary arteries over a 12-month period. This innovative approach aims to explore

Cereno Scientific launches sub-study on drug candidate CS1 for Pulmonary Arterial Hypertension, February 19, 2025 Read Post »

My journey with pulmonary hypertension: From diagnosis to thriving, Hall Skaara, International Journal of Cardiology Congenital Heart Disease, March 2025

Hall Skaara is a pulmonary arterial hypertension patient. His article about life as a patient has been published in the International Journal of Cardiology: Congenital Heart Disease. Hall was diagnosed with idiopathic pulmonary hypertension after cardiac issues and two ablations, but has transformed his diagnosis into an opportunity to help others. Despite physical limitations, he

My journey with pulmonary hypertension: From diagnosis to thriving, Hall Skaara, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

TRANSLATE »
Scroll to Top